ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has earned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $3.30.

ALXO has been the topic of a number of research analyst reports. Jefferies Financial Group raised shares of ALX Oncology from a “hold” rating to a “buy” rating and boosted their price objective for the company from $2.00 to $3.00 in a research report on Thursday, March 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Friday, January 24th. UBS Group lowered their price objective on shares of ALX Oncology from $1.20 to $1.00 and set a “buy” rating on the stock in a research report on Wednesday. HC Wainwright lowered their price objective on shares of ALX Oncology from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Finally, Piper Sandler boosted their price objective on shares of ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th.

ALX Oncology Stock Down 4.6%

ALXO stock opened at $0.41 on Thursday. ALX Oncology has a 52-week low of $0.41 and a 52-week high of $15.35. The company’s 50 day simple moving average is $0.56 and its 200-day simple moving average is $1.12. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The firm has a market capitalization of $21.84 million, a P/E ratio of -0.14 and a beta of 1.21.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.11). As a group, equities research analysts anticipate that ALX Oncology will post -2.76 EPS for the current year.

Institutional Trading of ALX Oncology

Large investors have recently added to or reduced their stakes in the business. Barclays PLC grew its position in ALX Oncology by 243.6% in the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after acquiring an additional 42,185 shares in the last quarter. Sei Investments Co. bought a new stake in ALX Oncology in the fourth quarter worth approximately $102,000. Geode Capital Management LLC grew its position in ALX Oncology by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 740,106 shares of the company’s stock worth $1,236,000 after acquiring an additional 39,259 shares in the last quarter. JPMorgan Chase & Co. grew its position in ALX Oncology by 476.7% in the fourth quarter. JPMorgan Chase & Co. now owns 236,046 shares of the company’s stock worth $394,000 after acquiring an additional 195,112 shares in the last quarter. Finally, Bank of Montreal Can bought a new stake in ALX Oncology in the fourth quarter worth approximately $1,380,000. 97.97% of the stock is owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.